KR101850925B1 - 폴리머라아제 억제를 위한 방법 및 조성물 - Google Patents

폴리머라아제 억제를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101850925B1
KR101850925B1 KR1020137012318A KR20137012318A KR101850925B1 KR 101850925 B1 KR101850925 B1 KR 101850925B1 KR 1020137012318 A KR1020137012318 A KR 1020137012318A KR 20137012318 A KR20137012318 A KR 20137012318A KR 101850925 B1 KR101850925 B1 KR 101850925B1
Authority
KR
South Korea
Prior art keywords
influenza
virus
viral
group
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137012318A
Other languages
English (en)
Korean (ko)
Other versions
KR20140040676A (ko
Inventor
샨타 반티아
프라빈 엘. 코티안
야라가다 에스. 바부
Original Assignee
바이오크리스트파마슈티컬즈,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오크리스트파마슈티컬즈,인코포레이티드 filed Critical 바이오크리스트파마슈티컬즈,인코포레이티드
Publication of KR20140040676A publication Critical patent/KR20140040676A/ko
Application granted granted Critical
Publication of KR101850925B1 publication Critical patent/KR101850925B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137012318A 2010-10-15 2011-10-14 폴리머라아제 억제를 위한 방법 및 조성물 Active KR101850925B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39352210P 2010-10-15 2010-10-15
US61/393,522 2010-10-15
US201161492054P 2011-06-01 2011-06-01
US61/492,054 2011-06-01
PCT/US2011/056421 WO2012051570A1 (en) 2010-10-15 2011-10-14 Methods and compositions for inhibition of polymerase

Publications (2)

Publication Number Publication Date
KR20140040676A KR20140040676A (ko) 2014-04-03
KR101850925B1 true KR101850925B1 (ko) 2018-04-20

Family

ID=45938737

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137012318A Active KR101850925B1 (ko) 2010-10-15 2011-10-14 폴리머라아제 억제를 위한 방법 및 조성물

Country Status (23)

Country Link
US (6) US20130331404A1 (OSRAM)
EP (3) EP2898885B1 (OSRAM)
JP (2) JP5902698B2 (OSRAM)
KR (1) KR101850925B1 (OSRAM)
CN (1) CN103429245B (OSRAM)
AU (2) AU2011315902B2 (OSRAM)
BR (1) BR112013009029B1 (OSRAM)
CA (1) CA2813783C (OSRAM)
CY (1) CY1119880T1 (OSRAM)
DK (2) DK2627334T3 (OSRAM)
ES (2) ES2536831T3 (OSRAM)
HR (2) HRP20150487T1 (OSRAM)
HU (1) HUE036387T2 (OSRAM)
IL (1) IL225672B (OSRAM)
LT (1) LT2898885T (OSRAM)
MX (1) MX348759B (OSRAM)
PL (2) PL2627334T3 (OSRAM)
PT (2) PT2627334E (OSRAM)
RS (2) RS56870B1 (OSRAM)
RU (3) RU2599013C2 (OSRAM)
SI (2) SI2627334T1 (OSRAM)
SM (2) SMT201800064T1 (OSRAM)
WO (1) WO2012051570A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002844A (ko) * 2012-04-18 2015-01-07 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130048T1 (hr) 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
WO2011035250A1 (en) 2009-09-21 2011-03-24 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
MX348759B (es) * 2010-10-15 2017-06-28 Biocryst Pharm Inc Metodos y composiciones para inhibicion de polimerasa.
WO2014078778A2 (en) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
CA2911424C (en) 2013-05-14 2021-11-30 Biocryst Pharmaceuticals, Inc. Anti-influenza imino-ribose pyrrolopyrimidine derivatives
TWI678369B (zh) * 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN104513249B (zh) * 2014-12-26 2016-08-31 苏州明锐医药科技有限公司 抗埃博拉病毒药物bcx4430的制备方法
HRP20220355T1 (hr) 2015-09-16 2022-05-13 Gilead Sciences, Inc. Postupci za liječenje infekcija coronaviridae
WO2017155886A1 (en) 2016-03-06 2017-09-14 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of zika virus infection
DE102016002873A1 (de) 2016-03-09 2016-05-25 Heinz Kiefer Zellnachweisverfahren und Screeningverfahren von Stoffbibliotheken zur Identifizierung von Einzelstoffen, die im Falle einer bioterroristischen Bedrohung gegen Mischungen synthetischer Viren wirksam sind
CN116036112A (zh) 2017-03-14 2023-05-02 吉利德科学公司 治疗猫冠状病毒感染的方法
WO2018204198A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP4512475A3 (en) 2017-07-11 2025-05-14 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN118994170A (zh) 2020-03-12 2024-11-22 吉利德科学公司 制备1'-氰基核苷的方法
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021207386A1 (en) * 2020-04-07 2021-10-14 Biocryst Pharmaceuticals, Inc. Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CA3187821A1 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20240285557A1 (en) * 2021-06-25 2024-08-29 Industry Foundation Of Chonnam National University Pharmaceutical composition comprising lipase inhibitor for treatment or treatment of rna viral infections
KR102871928B1 (ko) * 2021-06-25 2025-10-20 전남대학교 산학협력단 지방분해효소 억제제를 포함하는 rna 바이러스 감염증 예방 또는 치료용 약제학적 조성물
JP2024531898A (ja) 2021-08-17 2024-09-03 サウスウエスト リサーチ インスティテュート コロナウイルスに対する阻害剤
CN115925640B (zh) * 2021-08-23 2025-03-28 中国人民解放军军事科学院军事医学研究院 ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用
US12552827B2 (en) 2022-01-21 2026-02-17 Biocryst Pharmaceuticals, Inc. Synthesis of an antiviral azasugar triphosphate
TW202525810A (zh) 2022-03-02 2025-07-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN118359621B (zh) * 2024-04-16 2025-05-16 上海陶术生物科技股份有限公司 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体
CN118359622B (zh) * 2024-04-16 2025-08-26 上海陶术生物科技股份有限公司 加利司伟中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100009A2 (en) 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
US20100143300A1 (en) 2005-03-29 2010-06-10 Babu Yarlagadda S Hepatitis c therapies
WO2012063085A2 (en) 2010-11-11 2012-05-18 Redx Pharma Limited Drug derivatives
WO2013158746A1 (en) 2012-04-18 2013-10-24 Biocryst Pharmaceuticals, Inc. Compositions and methods for inhibiting viral polymerase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
WO2006002231A1 (en) * 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
CN101528749B (zh) 2006-09-07 2013-07-31 工业研究有限公司 核苷磷酸化酶和水解酶的无环胺抑制剂
EA016830B1 (ru) 2006-09-11 2012-07-30 Саузерн Рисерч Инститьют Азольные нуклеозиды и их применение в качестве ингибиторов вариальных рнк- и днк-полимераз
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
MX348759B (es) * 2010-10-15 2017-06-28 Biocryst Pharm Inc Metodos y composiciones para inhibicion de polimerasa.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100009A2 (en) 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
US20100143300A1 (en) 2005-03-29 2010-06-10 Babu Yarlagadda S Hepatitis c therapies
WO2012063085A2 (en) 2010-11-11 2012-05-18 Redx Pharma Limited Drug derivatives
WO2013158746A1 (en) 2012-04-18 2013-10-24 Biocryst Pharmaceuticals, Inc. Compositions and methods for inhibiting viral polymerase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150002844A (ko) * 2012-04-18 2015-01-07 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법
KR102156819B1 (ko) 2012-04-18 2020-09-16 바이오크리스트파마슈티컬즈,인코포레이티드 바이러스 폴리머라아제를 억제하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
CN103429245A (zh) 2013-12-04
SMT201800064T1 (it) 2018-03-08
EP2627334B1 (en) 2015-04-29
RU2016134401A (ru) 2018-12-10
AU2017200471A1 (en) 2017-02-23
CA2813783A1 (en) 2012-04-19
RS54072B1 (sr) 2015-10-30
US20190374544A1 (en) 2019-12-12
RU2020111042A (ru) 2021-09-17
RU2599013C2 (ru) 2016-10-10
US20130331404A1 (en) 2013-12-12
PL2627334T3 (pl) 2015-08-31
CA2813783C (en) 2019-01-22
WO2012051570A1 (en) 2012-04-19
DK2627334T3 (en) 2015-05-18
BR112013009029A2 (en) 2018-06-19
US20180360836A1 (en) 2018-12-20
ES2657687T3 (es) 2018-03-06
HK1257363A1 (en) 2019-10-18
HK1212914A1 (en) 2016-06-24
IL225672A0 (en) 2013-06-27
US9492452B2 (en) 2016-11-15
MX2013003938A (es) 2013-07-05
CY1119880T1 (el) 2018-06-27
DK2898885T3 (en) 2018-02-05
RU2013121794A (ru) 2014-11-20
PT2898885T (pt) 2018-02-05
AU2017200471B2 (en) 2018-04-12
SI2898885T1 (en) 2018-03-30
CN103429245B (zh) 2016-10-05
MX348759B (es) 2017-06-28
HRP20150487T1 (hr) 2015-08-28
PL2898885T3 (pl) 2018-04-30
US10022375B2 (en) 2018-07-17
JP5902698B2 (ja) 2016-04-13
US10420769B2 (en) 2019-09-24
BR112013009029B1 (pt) 2021-06-29
LT2898885T (lt) 2018-02-26
SI2627334T1 (sl) 2015-08-31
AU2011315902B2 (en) 2016-11-17
RU2718690C2 (ru) 2020-04-13
JP2013544788A (ja) 2013-12-19
RS56870B1 (sr) 2018-04-30
US20170042901A1 (en) 2017-02-16
EP2627334A4 (en) 2014-04-16
EP3345605A1 (en) 2018-07-11
EP2898885A1 (en) 2015-07-29
US11173159B2 (en) 2021-11-16
AU2011315902A1 (en) 2013-05-30
US20150051230A1 (en) 2015-02-19
US12508266B2 (en) 2025-12-30
HUE036387T2 (hu) 2018-07-30
JP2016135790A (ja) 2016-07-28
HRP20180220T1 (hr) 2018-03-09
US20220040190A1 (en) 2022-02-10
EP2898885B1 (en) 2017-11-22
SMT201500148B (it) 2015-09-07
EP2627334A1 (en) 2013-08-21
RU2016134401A3 (OSRAM) 2020-01-24
ES2536831T3 (es) 2015-05-29
KR20140040676A (ko) 2014-04-03
EP3345605B1 (en) 2019-11-20
IL225672B (en) 2019-02-28
PT2627334E (pt) 2015-07-07

Similar Documents

Publication Publication Date Title
US12508266B2 (en) Methods and compositions for inhibition of polymerase
JP6417568B2 (ja) 抗インフルエンザ組成物及び方法
US20260137688A1 (en) Methods and compositions for inhibition of polymerase
HK1257363B (en) Pyrrolopyrimidine derivatives for use in the inhibition of polymerase
HK1191565B (en) Methods and compositions for inhibition of polymerase
HK1191565A (en) Methods and compositions for inhibition of polymerase
HK1212914B (en) Pyrrolopyrimidine derivatives for use in the treatment of viral infections

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9